Dihydralazine
- Generic Name
- Dihydralazine
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10N6
- CAS Number
- 484-23-1
- Unique Ingredient Identifier
- PCU411F5L6
- Background
Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
- Indication
用于治疗高血压或心力衰竭。
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
Phase 3
Recruiting
- Conditions
- Aortic Stenosis, Severe
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- University Medical Center Goettingen
- Target Recruit Count
- 300
- Registration Number
- NCT05230901
- Locations
- 🇩🇪
University Medical Center Göttingen, Göttingen, Lower Saxony, Germany
The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals
Phase 4
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 16
- Registration Number
- NCT00311974
- Locations
- 🇩🇰
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath